Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease
- PMID: 21950746
- DOI: 10.1111/j.1440-1746.2011.06774.x
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease
Abstract
Background and aim: Significant hepatic fibrosis is prognostic of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD); however, it remains unclear whether non-invasive fibrosis models can determine this end-point. We therefore compared the accuracy of simple bedside versus complex fibrosis models across a range of fibrosis in a multi-centre NAFLD cohort.
Methods: Simple (APRI, BARD) and complex (Hepascore, Fibrotest, FIB4) fibrosis models were calculated in 242 NAFLD subjects undergoing liver biopsy. Significant (F2-4) and advanced fibrosis (F3,4) were defined using Kleiner criteria. Models were compared using area under the receiver operator characteristic curves (AUC). Cut-offs were determined by Youden Index or 90% predictive values.
Results: For significant fibrosis, non-invasive fibrosis models had modest accuracy (AUC 0.707-0.743) with BARD being least accurate (AUC 0.609, P < 0.05 vs others). Using single cut-offs, sensitivities and predictive values were < 80%; using two cut-offs, > 75% of subjects fell within indeterminate ranges. Simple models had significantly more subjects within indeterminate ranges than complex models (99.1-100% vs 82.1-84.4% respectively, P < 0.05 for all). For advanced fibrosis, complex models were more accurate than BARD (AUC 0.802-0.858 vs 0.701, P < 0.05). Using two cut-offs, complex models had fewer individuals within indeterminate ranges than BARD (11.1-32.3% vs 70.7%, P < 0.01 for all). For cirrhosis, complex models had higher AUC values than simple models.
Conclusions: In NAFLD subjects, non-invasive models have modest accuracy for determining significant fibrosis and have predictive values less than 90% in the majority of subjects. Complex models are more accurate than simple bedside models across a range of fibrosis.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
Similar articles
-
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077. Gut. 2010. PMID: 20801772
-
Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.J Gastroenterol Hepatol. 2011 Sep;26(9):1411-6. doi: 10.1111/j.1440-1746.2011.06760.x. J Gastroenterol Hepatol. 2011. PMID: 21557768
-
Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.Aliment Pharmacol Ther. 2008 Nov 15;28(10):1188-98. doi: 10.1111/j.1365-2036.2008.03831.x. Epub 2008 Aug 14. Aliment Pharmacol Ther. 2008. PMID: 18705692
-
Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.Clin Liver Dis. 2007 Feb;11(1):25-35, viii. doi: 10.1016/j.cld.2007.02.004. Clin Liver Dis. 2007. PMID: 17544970 Review.
-
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.Eur J Gastroenterol Hepatol. 2009 Jan;21(1):28-38. doi: 10.1097/MEG.0b013e32830cebd7. Eur J Gastroenterol Hepatol. 2009. PMID: 19060630 Review.
Cited by
-
The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery.Langenbecks Arch Surg. 2016 Mar;401(2):195-203. doi: 10.1007/s00423-016-1389-0. Epub 2016 Mar 4. Langenbecks Arch Surg. 2016. PMID: 26943655
-
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077. World J Gastroenterol. 2015. PMID: 26494963 Free PMC article. Review.
-
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.Endocrinol Metab (Seoul). 2020 Mar;35(1):165-176. doi: 10.3803/EnM.2020.35.1.165. Endocrinol Metab (Seoul). 2020. PMID: 32207277 Free PMC article.
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.Front Nutr. 2024 Feb 14;11:1284509. doi: 10.3389/fnut.2024.1284509. eCollection 2024. Front Nutr. 2024. PMID: 38419854 Free PMC article.
-
Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.Cureus. 2024 Oct 14;16(10):e71451. doi: 10.7759/cureus.71451. eCollection 2024 Oct. Cureus. 2024. PMID: 39544615 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous